Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect In Pancreatic Murine Tumor Models At ESTRO 2024 Congress In Glasgow; Initial Data Demonstrates Reduction In Distant Pancreatic Cancer Tumor Growth Rate Starting From 3-Weeks...
Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect In Pancreatic Murine Tumor Models At ESTRO 2024 Congress In Glasgow; Initial Data Demonstrates Reduction In Distant Pancreatic Cancer Tumor Growth Rate Starting From 3-Weeks...
Alpha Tau在格拉斯哥的ESTRO 2024大會上公佈了臨床前數據，表明胰腺鼠腫瘤模型的腹腔免疫效應；初步數據顯示，從3周開始，遠距離胰腺癌腫瘤的生長速度會降低...
Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect In Pancreatic Murine Tumor Models At ESTRO 2024 Congress In Glasgow; Initial Data Demonstrates Reduction In Distant Pancreatic Cancer Tumor Growth Rate Starting From 3-Weeks After First Tumor Is Treated With Alpha Dart Alone
Alpha Tau在格拉斯哥的ESTRO 2024大會上公佈了臨床前數據，顯示胰腺鼠腫瘤模型的腹腔免疫效應；初步數據顯示，從單獨使用Alpha Dart治療第一個腫瘤後的3周開始，遠距離胰腺癌腫瘤的生長率會降低
- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT alone
-初步數據顯示，從單獨使用Alpha Dart治療第一個腫瘤後的三週開始，遠端胰腺癌腫瘤的生長率顯著降低
- Effect seen across both Panc02 and KPC tumor models -
-在 Panc02 和 KPC 腫瘤模型中均可見效果-
JERUSALEM, May 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))))), the developer of the innovative alpha-radiation cancer therapy...
耶路撒冷，2024年5月6日（環球通訊社）——創新...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。